{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:04:24Z","timestamp":1792461864660,"version":"4.5.0"},"reference-count":27,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Infigratinib (BGJ398) is a potent and selective fibroblast grown factor receptor 1 to 3 (FGFR1\u20103) inhibitor with significant activity in patients with advanced or metastatic urothelial carcinoma bearing\n                      <jats:italic>FGFR3<\/jats:italic>\n                      alterations. Given the distinct biologic characteristics of upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB), the authors examined whether infigratinib had varying activity in these settings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Eligible patients had metastatic urothelial carcinoma with activating\n                      <jats:italic>FGFR3<\/jats:italic>\n                      mutations and\/or fusions. Comprehensive genomic profiling was performed on formalin\u2010fixed, paraffin\u2010embedded tissues. Blood was collected for cell\u2010free DNA analysis using a 600\u2010gene panel. Patients received infigratinib at a dose of 125\u00a0mg orally daily (3\u00a0weeks on\/1\u00a0week off) until disease progression or intolerable toxicity occurred. The overall response rate (ORR; partial response [PR] plus complete response [CR]) and disease control rate (DCR; CR plus PR plus stable disease [SD]) were characterized.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 67 patients were enrolled; the majority (70.1%) had received \u22652 prior antineoplastic therapies. In 8 patients with UTUC, 1 CR and 3 PRs were observed (ORR, 50%); the remaining patients achieved a best response of SD (DCR, 100%). In patients with UCB, 13 PRs were observed (ORR, 22%), and 22 patients had a best response of SD (DCR, 59.3%). Notable differences in genomic alterations between patients with UTUC and those with UCB included higher frequencies of\n                      <jats:italic>FGFR3\u2010TACC3<\/jats:italic>\n                      fusions (12.5% vs 6.8%) and\n                      <jats:italic>FGFR3 R248C<\/jats:italic>\n                      mutations (50% vs 11.9%), and a lower frequency of\n                      <jats:italic>FGFR3 S249C<\/jats:italic>\n                      mutations (37.5% vs 59.3%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Differences in the cumulative genomic profile were observed between patients with UTUC and those with UCB in the current\n                      <jats:italic>FGFR3<\/jats:italic>\n                      \u2010restricted experience, underscoring the distinct biology of these diseases. These results support a planned phase 3 adjuvant study predominantly performed in this population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.32806","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T12:35:48Z","timestamp":1585053348000},"page":"2597-2606","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and\/or cell\u2010free DNA results"],"prefix":"10.1002","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0848","authenticated-orcid":false,"given":"Sumanta K.","family":"Pal","sequence":"first","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics City of Hope Comprehensive Cancer Center Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Bajorin","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center New York New York"},{"name":"Department of Medicine Weill Cornell Medical College New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazli","family":"Dizman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics City of Hope Comprehensive Cancer Center Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Hoffman\u2010Censits","sequence":"additional","affiliation":[{"name":"Departments of Medical Oncology and Urology Sidney Kimmel Cancer Center, Thomas Jefferson University Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Quinn","sequence":"additional","affiliation":[{"name":"University of Southern California Norris Comprehensive Cancer Center Keck School of Medicine at USC Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Petrylak","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology Yale School of Medicine New Haven Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Tisch Cancer Institute The Mount Sinai Hospital New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-4571","authenticated-orcid":false,"given":"Ulka","family":"Vaishampayan","sequence":"additional","affiliation":[{"name":"Department of Oncology Karmanos Cancer Institute, Wayne State University Detroit Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Scientific Institute of Romagna for the Study and Treatment of Cancer IRCCS Meldola Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumati","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Huntsman Cancer Institute, University of Utah Salt Lake City Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute and Tennessee Oncology Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harris S.","family":"Soifer","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine QED Therapeutics Inc San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine QED Therapeutics Inc San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Management QED Therapeutics Inc San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl L.","family":"Dambkowski","sequence":"additional","affiliation":[{"name":"Department of Strategy and Operations QED Therapeutics Inc San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Moran","sequence":"additional","affiliation":[{"name":"Department of Clinical Development QED Therapeutics Inc San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[{"name":"Institute of Urology Keck School of Medicine, University of Southern California Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Department of Medicine Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.757"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0775-5"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33297-X"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30065-7"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30900-2"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9761"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.149"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.419"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.10.006"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29826"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.025"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.05.048"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2039"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0229"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.2048"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1015"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0589"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.4513"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.409"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10873-y"},{"key":"e_1_2_8_24_1","article-title":"Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy","volume":"5","author":"Winters BR","year":"2019","journal-title":"JCI Insight"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31314"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0143"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx405"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14000"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.32806","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32806","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.32806","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:05:31Z","timestamp":1761869131000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.32806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1002\/cncr.32806"],"URL":"https:\/\/doi.org\/10.1002\/cncr.32806","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737623683.793578106","asserted-by":"object"}]},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"assertion":[{"value":"2019-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}